ARTA
ABUS icon

A.R.T. Advisors’s Arbutus Biopharma ABUS Stock Holding History

A.R.T. Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-14,140
Closed -$26K – 70
2020
Q2 		$26K Buy
+14,140
New +$23.1K 0.04% 247
2020
Q1 		– Sell
-10,780
Closed -$30K – 37
2019
Q4 		$30K Sell
10,780
-10,894
-50% -$17.6K ﹤0.01% 1270
2019
Q3 		$33K Sell
21,674
-13,775
-39% -$23.7K ﹤0.01% 1345
2019
Q2 		$74K Buy
+35,449
New +$90.7K ﹤0.01% 1222
2019
Q1 		– Sell
-35,658
Closed -$137K – 1267
2018
Q4 		$137K Sell
35,658
-1,333
-4% -$6.57K 0.01% 1125
2018
Q3 		$349K Buy
+36,991
New +$367K 0.02% 986
2018
Q2 		– Sell
-14,491
Closed -$72K – 1373
2018
Q1 		$72K Sell
14,491
-38,991
-73% -$206K ﹤0.01% 1379
2017
Q4 		$270K Buy
53,482
+36,600
+217% +$215K 0.01% 1088
2017
Q3 		$104K Buy
+16,882
New +$72.2K 0.01% 1206
2015
Q4 		– Sell
-22,617
Closed -$137K – 1427
2015
Q3 		$137K Buy
+22,617
New +$201K 0.01% 1221
2014
Q4 		– Sell
-66,583
Closed -$1.41M – 1384
2014
Q3 		$1.41M Buy
+66,583
New +$1.09M 0.07% 409
2014
Q1 		– Sell
-26,832
Closed -$213K – 1296
2013
Q4 		$213K Buy
+26,832
New +$224K 0.01% 1097

Other funds holding ABUS

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TI
Think Investments San Francisco, California $847M AUM 88.1% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

A.R.T. Advisors's ABUS Position: Q3 2020 in Review

A.R.T. Advisors sold out of Arbutus Biopharma (ABUS) in Q3 2020, closing a stake of 14,140 shares — an estimated $26K sold.

A.R.T. Advisors first reported a position in ABUS in Q4 2013 and held it in 12 quarters. The position peaked at $1.41M in Q3 2014. 65 funds tracked by Wall St. Rank hold ABUS as of Q3 2020.

  • A.R.T. Advisors reported no remaining Arbutus Biopharma position as of Q3 2020 after selling out during the quarter.
  • A.R.T. Advisors sold 14,140 Arbutus Biopharma shares in Q3 2020, an estimated $26K.
  • A.R.T. Advisors first reported a position in Arbutus Biopharma in Q4 2013 and held it in 12 quarters.
  • A.R.T. Advisors's Arbutus Biopharma position peaked at $1.41M in Q3 2014.
  • 65 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2020.

Based on A.R.T. Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.